| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6025391 | NOVARTIS | Enteric-coated pharmaceutical compositions of mycophenolate |
Apr, 2017
(7 years ago) | |
| US6172107 | NOVARTIS | Entric-coated pharmaceutical compositions |
Apr, 2017
(7 years ago) | |
| US6306900 | NOVARTIS | Enteric coated pharmaceutical compositions |
Feb, 2018
(6 years ago) | |
Myfortic is owned by Novartis.
Myfortic contains Mycophenolic Sodium.
Myfortic has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Myfortic are:
- US6025391
- US6172107
- US6306900
Myfortic was authorised for market use on 27 February, 2004.
Myfortic is available in tablet, delayed release;oral dosage forms.
Myfortic can be used as prophylaxis of organ rejection in patients receiving allogeneic renal transplants.
The generics of Myfortic are possible to be released after 27 February, 2018.
Drugs and Companies using MYCOPHENOLIC SODIUM ingredient
Market Authorisation Date: 27 February, 2004
Treatment: Prophylaxis of organ rejection in patients receiving allogeneic renal transplants
Dosage: TABLET, DELAYED RELEASE;ORAL
MYFORTIC family patents
